|
ИСТИНА |
Войти в систему Регистрация |
ИСТИНА ЦЭМИ РАН |
||
Evaluation of VEGF and VEGFR gene expression as prognostic markers in low and intermediate‑1 risk patients with myelodysplastic syndromesстатья Электронная публикация
- Авторы: Kalitin Nikolay, Dudina Galina, Kostritsa Natalia, Sivirinova Anastasiya, Karamysheva Aida
- Журнал: Oncology Letters
- Том: 25
- Номер: 3
- Год издания: 2023
- Издательство: Spandidos Publications
- Местоположение издательства: Greece
- Номер статьи: 95
- DOI: 10.3892/ol.2023.13681
- Аннотация: Vascular endothelial growth factors (VEGFs) are angiogenic factors playing a key role in tumor development. VEGFs are produced by different normal and tumor cells, including platelets, lymphocytes and mononuclear cells of peripheral blood. VEGF (VEGF‑A, VEGF‑C and VEGF‑D) and VEGFR (VEGFR1, VEGFR2 and VEGFR3) gene expression was studied in patients with myelodysplastic syndrome (MDS) to evaluate the possible prognostic role of the expression of these genes. Gene expression levels were determined using peripheral blood samples of 51 patients with MDS and 15 healthy volunteers by quantitative PCR. Expression of all VEGF and VEGFR genes was elevated in patients with MDS compared with healthy volunteers. No association of VEGF‑A expression with the hemoglobin content in peripheral blood was found. The analyses of gene expression in patients with MDS stratified by risk groups according to the International Prognostic Scoring System showed progressive augmentation of VEGF‑A gene expression from low to high‑risk groups and VEGFR1 and VEGFR2 expression from intermediate‑1 to high‑risk groups. The statistically significant difference in survival time of patients with high and low levels of VEGFR1 expression was revealed. VEGF‑A/VEGFR1 expression may be important for risk evaluation of patients with MDS.
- Добавил в систему: Калитин Николай Николаевич